RxDoctor Payments DataLook up a doctor →

Scott Litwiller, MD

Urology · Tulsa, OKNPI 1558382028

Payments from drug & device makers

$27,008in general payments, 2019–2025

Across 448 payments — averaging $60.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$11K
  • Astellas Pharma US Inc$9K
  • Sumitomo Pharma America, Inc.$851
  • Medtronic$700
  • Johnson & Johnson$558
  • AbbVie$487
  • plus $5K from 38 others

What the payments were for

  • Consulting fees$7,96730%
  • Speaking & faculty fees$7,82029%
  • Travel & lodging$1,2365%
  • Food & beverage$9,98437%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,008 in reported general payments places this provider in the 90th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$278,571
Medicare patients
787
Services billed
13,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron310$204,277
MyrbetriqMirabegron161$99,722
Estradiol406$29,213
Solifenacin Succinate473$22,813
PremarinEstrogens, Conjugated45$14,928
Fesoterodine Fumarate ErFesoterodine Fumarate42$4,644
Trospium Chloride122$4,438
YuvafemEstradiol38$3,423
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst233$3,000
MovantikNaloxegol Oxalate24$1,946
Methenamine Hippurate12$1,034
Tamsulosin Hcl113$1,018
Desmopressin Acetate20$1,003
Cephalexin106$900
Amitriptyline Hcl36$491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$851$204,277310 claims
Astellas Pharma US IncMyrbetriq$8,688$99,722161 claims
PfizerPremarin$393$14,92845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 145 urology providers in Oklahoma.

Other urology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →